PMID- 19262900
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 1934-7820 (Print)
IS  - 1934-7987 (Electronic)
IS  - 1934-7820 (Linking)
VI  - 1
IP  - 6
DP  - 2007 Nov
TI  - HER Receptor Family: Novel Candidate for Targeted Therapy for Gallbladder and 
      Extrahepatic Bile Duct Cancer.
PG  - 221-7
AB  - PURPOSE: Biliary tract cancers (BTC) are uncommon in the United States, but are 
      endemic in parts of South America and Asia. BTCs are aggressive tumors associated 
      with poor survival. Activation of HER-2/neu (erbB2) and/or epidermal growth 
      factor receptor (EGFR) are important in breast, colon, and lung cancers. Tumor 
      specimens from patients from the United States and Chile were examined for 
      expression of HER-2/neu, EGFR, and their activated forms (p-erbB2, p-EGFR). 
      MATERIALS AND METHODS: Specimens from 77 gallbladder cancers (GBC), 16 
      extrahepatic bile duct cancers (EHBDC), 21 intrahepatic bile duct cancers 
      (IHBDC), 11 cases of cholecystitis (CHOLE), and 8 normal gallbladders (NGB) were 
      examined for HER-2/neu, p-erbB2, EGFR, and p-EGFR expression by 
      immunohistochemistry (IHC), with scores of 2+ or 3+ defined as positive. 
      HER-2/neu gene amplification was analyzed by double color HER-2/neu 
      gene/chromosome 17 centromere (CEP17) fluorescence in situ hybridization (FISH) 
      assays RESULTS: HER-2/neu-positive IHC staining was found in 31.2% of GBC, 31.3%, 
      of EHBDC, and 33.3% of IHBDC; 12.5% of CHOLE specimens showed 2+ staining and the 
      remaining CHOLE and NGB were negative. HER-2/neu gene amplification was detected 
      in 20.9% of GBC, 21.4% of EHBDC, and none of IHBDC. There was a significant 
      correlation between IHC 2+ and 3+ and gene amplification (P =.0001). CONCLUSIONS: 
      HER-2/neu amplification was identified in more than 20% of GB and EHBDC. There 
      was strong correlation between HER-2/neu IHC and FISH positivity. These findings 
      indicate a role for HER-2/neu in some subsets of BTC, and provide a rationale for 
      study of HER-2/neu-directed therapies in this setting.
FAU - Kawamoto, Toru
AU  - Kawamoto T
AD  - Department of Gastrointestinal Medical Oncology, The University of Texas, M. D. 
      Anderson Cancer Center, Houston, TX.
FAU - Krishnamurthy, Savitri
AU  - Krishnamurthy S
FAU - Tarco, Emily
AU  - Tarco E
FAU - Trivedi, Smita
AU  - Trivedi S
FAU - Wistuba, Ignacio I
AU  - Wistuba II
FAU - Li, Donghui
AU  - Li D
FAU - Roa, Ivan
AU  - Roa I
FAU - Roa, Juan C
AU  - Roa JC
FAU - Thomas, Melanie B
AU  - Thomas MB
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastrointest Cancer Res
JT  - Gastrointestinal cancer research : GCR
JID - 101300691
PMC - PMC2631213
EDAT- 2007/11/01 00:00
MHDA- 2007/11/01 00:01
PMCR- 2007/11/01
CRDT- 2009/03/06 09:00
PHST- 2007/05/30 00:00 [received]
PHST- 2007/09/17 00:00 [accepted]
PHST- 2009/03/06 09:00 [entrez]
PHST- 2007/11/01 00:00 [pubmed]
PHST- 2007/11/01 00:01 [medline]
PHST- 2007/11/01 00:00 [pmc-release]
AID - gcr1_6p0221 [pii]
PST - ppublish
SO  - Gastrointest Cancer Res. 2007 Nov;1(6):221-7.